{"id":527145,"date":"2010-04-14T08:30:03","date_gmt":"2010-04-14T12:30:03","guid":{"rendered":"http:\/\/www.xconomy.com\/?p=73400"},"modified":"2010-04-14T08:30:03","modified_gmt":"2010-04-14T12:30:03","slug":"third-rock-eying-400m-second-fund","status":"publish","type":"post","link":"https:\/\/mereja.media\/index\/527145","title":{"rendered":"Third Rock Eying $400M Second Fund"},"content":{"rendered":"\n<div style=\"text-transform:uppercase\"><a href=\"http:\/\/www.xconomy.com\/tag\/Life-Sciences\/\">Life Sciences<\/a>, <a href=\"http:\/\/www.xconomy.com\/tag\/deals\/\">deals<\/a>, <a href=\"http:\/\/www.xconomy.com\/tag\/VC\/\">VC<\/a><\/div>\n<p>\t\t<strong>Ryan McBride wrote:<\/strong><\/p>\n<p><a href=\"http:\/\/www.xconomy.com\/boston\/2008\/09\/23\/third-rock-ventures-heads-back-to-the-basics-nurtures-disruptive-life-sciences-companies\/\">Third Rock Ventures<\/a>, a Boston venture firm focused on life sciences investments, has filed papers with the SEC to raise a second fund. The proposed amount of the new fund is $400 million, yet the paperwork indicates that none of those funds had been raised as of the April 9 <a href=\"http:\/\/www.sec.gov\/Archives\/edgar\/data\/1488495\/000148849510000001\/xslFormDX01\/primary_doc.xml\">filing<\/a>. Still, this is good news for early-stage biotech startups, which have been the sweet spot for Third Rock&#8217;s maiden fund of $378 million, closed in 2007.<\/p>\n<div class=\"postFooter\"><a href=\"http:\/\/www.xconomy.com\/boston\/2010\/04\/14\/third-rock-eying-400m-second-fund\/#comments\">Comments<\/a> | <a href=http:\/\/www.xconomy.com\/reprints\/>Reprints<\/a> | Share: &nbsp;<br \/>\n<a href=\"http:\/\/twitter.com\/home?status=RT%20@Xconomy%20Third%20Rock%20Eying%20$400M%20Second%20Fund%20http:\/\/xconomy.com\/?p=73400\"  rel=\"nofollow\"><img decoding=\"async\" src=\"http:\/\/www.xconomy.com\/wordpress\/wp-content\/themes\/xconomy\/images\/twitter.gif\" alt=\"Retweet\"\/><\/a><br \/>\n&nbsp;<a href=\"http:\/\/www.facebook.com\/sharer.php?u=http:\/\/www.xconomy.com\/boston\/2010\/04\/14\/third-rock-eying-400m-second-fund\/&#038;t=Third%20Rock%20Eying%20$400M%20Second%20Fund\"  rel=\"nofollow\"><img decoding=\"async\" src=\"http:\/\/www.xconomy.com\/wordpress\/wp-content\/themes\/xconomy\/images\/facebook.gif\" alt=\"Facebook\"\/><\/a><br \/>\n&nbsp;<a href=http:\/\/www.xconomy.com\/boston\/2010\/04\/14\/third-rock-eying-400m-second-fund\/email\/  rel=\"nofollow\"><img decoding=\"async\" src=\"http:\/\/www.xconomy.com\/wordpress\/wp-content\/themes\/xconomy\/images\/email.gif\" alt=\"Email\"\/><\/a><br \/>\n&nbsp;<a href=\"http:\/\/sharethis.com\/item?publisher=bfda184d-6684-4f7a-a23f-ca4ed4db9287&amp;title=Third+Rock+Eying+%24400M+Second+Fund&amp;url=http%3A%2F%2Fwww.xconomy.com%2Fboston%2F2010%2F04%2F14%2Fthird-rock-eying-400m-second-fund%2F\"><img decoding=\"async\" src=\"http:\/\/www.xconomy.com\/wordpress\/wp-content\/themes\/xconomy\/images\/share.gif\" alt=\"Share\"\/><\/a>\n<\/div>\n<p>\n\t\t\t<a href='http:\/\/d1.openx.org\/ck.php?bannerid=' ><br \/>\n\t\t\t<img src='http:\/\/d1.openx.org\/avw.php?bannerid=&amp;cb=279' border='0' alt='' \/><\/a><br \/>\n\t\t\t<br \/>\n\t\t\t\t<br clear=\"both\" style=\"clear: both;\"\/><br \/>\n<br clear=\"both\" style=\"clear: both;\"\/><br \/>\n<a href=\"http:\/\/ads.pheedo.com\/click.phdo?s=f46c352d67baec1876d7be96d171f37c&#038;p=1\"><img decoding=\"async\" alt=\"\" style=\"border: 0;\" border=\"0\" src=\"http:\/\/ads.pheedo.com\/img.phdo?s=f46c352d67baec1876d7be96d171f37c&#038;p=1\"\/><\/a><br \/>\n<img loading=\"lazy\" decoding=\"async\" alt=\"\" height=\"0\" width=\"0\" border=\"0\" style=\"display:none\" src=\"http:\/\/ib.adnxs.com\/seg?add=24595&#038;t=2\"\/><\/p>\n<p><a href=\"http:\/\/feedads.g.doubleclick.net\/~a\/KY0WWR7ifVxP7K7hQEIYOc1XNEg\/0\/da\"><img decoding=\"async\" src=\"http:\/\/feedads.g.doubleclick.net\/~a\/KY0WWR7ifVxP7K7hQEIYOc1XNEg\/0\/di\" border=\"0\" ismap=\"true\"><\/img><\/a><br \/>\n<a href=\"http:\/\/feedads.g.doubleclick.net\/~a\/KY0WWR7ifVxP7K7hQEIYOc1XNEg\/1\/da\"><img decoding=\"async\" src=\"http:\/\/feedads.g.doubleclick.net\/~a\/KY0WWR7ifVxP7K7hQEIYOc1XNEg\/1\/di\" border=\"0\" ismap=\"true\"><\/img><\/a><\/p>\n<p><img loading=\"lazy\" decoding=\"async\" src=\"http:\/\/feeds.feedburner.com\/~r\/Xconomy_Full\/~4\/zpYPZ5exUHc\" height=\"1\" width=\"1\"\/><\/p>\n","protected":false},"excerpt":{"rendered":"<p>Life Sciences, deals, VC Ryan McBride wrote: Third Rock Ventures, a Boston venture firm focused on life sciences investments, has filed papers with the SEC to raise a second fund. The proposed amount of the new fund is $400 million, yet the paperwork indicates that none of those funds had been raised as of the [&hellip;]<\/p>\n","protected":false},"author":2829,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[7],"tags":[],"class_list":["post-527145","post","type-post","status-publish","format-standard","hentry","category-news"],"_links":{"self":[{"href":"https:\/\/mereja.media\/index\/wp-json\/wp\/v2\/posts\/527145","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/mereja.media\/index\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/mereja.media\/index\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/mereja.media\/index\/wp-json\/wp\/v2\/users\/2829"}],"replies":[{"embeddable":true,"href":"https:\/\/mereja.media\/index\/wp-json\/wp\/v2\/comments?post=527145"}],"version-history":[{"count":0,"href":"https:\/\/mereja.media\/index\/wp-json\/wp\/v2\/posts\/527145\/revisions"}],"wp:attachment":[{"href":"https:\/\/mereja.media\/index\/wp-json\/wp\/v2\/media?parent=527145"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/mereja.media\/index\/wp-json\/wp\/v2\/categories?post=527145"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/mereja.media\/index\/wp-json\/wp\/v2\/tags?post=527145"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}